India's Supreme Court turned down Novartis' patent bid for an updated version of Glivec (imatinib mesylate), its blockbusting leukemia medication, saying that the updated compound "did not satisfy the test of novelty or inventiveness" required by the country's legislation. The ruling means that generic drugmakers can continue manufacturing and selling copies of Glivec at low prices... via Featured Health News from Medical News Today Read More Here..
Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/04/novartis-loses-in-patent-court-ruling_1.html
No comments:
Post a Comment